Bio-Techne Corp (TECH) Stock AnalysisTECHStock AnalysisBio-Techne Corp

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Bio-Techne Corp (TECH) is currently priced at $72.35, with a forward P/E of 34.60, indicating that while the stock has potential for growth, it is trading at a relatively high valuation compared to its earnings. The recent earnings report showed a net profit of $54.622 million for Q4 FY2026, a significant recovery from a loss in the same quarter last year, which is a positive sign. However, insider selling has increased by 174.32% over the last month, which raises concerns about confidence in the stock. Given these factors, it may be prudent to hold rather than buy at this time.

9 analysts cover TECH: 6 rate it Buy, 3 Hold and 0 Sell. The average price target is 66.14.